Top Health-care stocks:

JNJ: +0.2%

PFE: flat

ABT: flat

MRK: +0.1%

AMGN: +0.4%

Health-care shares were generally mixed in pre-market trading Friday.

In health-care stocks news, Alexion Pharmaceuticals ( ALXN ) said the National Institute for Health and Care Excellence Highly Specialised Technologies Evaluation Committee has recommended that Soliris be commissioned for all patients in England suffering from atypical hemolytic uremic syndrome, a severe and life-threatening ultra-rare disorder. Shares were unchanged during Friday's pre-market trading session at $194.72. Over the past 52 weeks, the stock has traded between $120.14 and $197.64.

Novartis AG ( NVS ) won faster approval for a heart-failure drug in the European Union, shortening the review period to 60 days. NVS said it expected to ask EU regulators early next year for approval to sell the drug, which it expected to be a "multi-blockbuster" with sales between $2 billion and $5 billion. It also expected to submit the drug to U.S. health regulators by next month. Shares were 1% higher during Friday's pre-market trading session at $96.48. Over the past 52 weeks, the stock has traded between $76.36 and $96.02.

Dynavax Technologies ( DVAX ), a biopharmaceutical company, said it has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors, following the expiration of a research and development collaboration and license agreement with GlaxoSmithKline ( GSK ). The company will now have global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications. Shares in were trading 4% lower at $14.50 during Friday's pre-market trading session. Over the past 52 weeks, the stock has traded between $12.50 and $21.40.

Go here to read the rest:

Health Care Sector Update for 11/28/2014: ALXN, NVS, DVAX